Another HIV vaccine is now on the market

Written by Ryn Gargulinski, CNN The Centers for Disease Control and Prevention (CDC) has announced that the alternative vaccine-boosting booster has proven highly protective against strains of the crippling human immunodeficiency virus (HIV) that…

Another HIV vaccine is now on the market

Written by Ryn Gargulinski, CNN

The Centers for Disease Control and Prevention (CDC) has announced that the alternative vaccine-boosting booster has proven highly protective against strains of the crippling human immunodeficiency virus (HIV) that can lead to AIDS.

In March 2018, Pfizer, the pharmaceutical company behind Prevenar 13, a 30-year-old HIV prevention vaccine, added a second booster to the product’s recommended package insert, the medical arm of a government health recommendation. It plans to begin marketing the booster early next year.

CDC says that evidence shows that people who get the second booster (called BTGN4) are more than 60% less likely to develop HIV than those who don’t. This means that those who might not get an HIV vaccine with the original Prevenar 13 end up with more protection than those who get the first booster, a sort of double-whammy to prevent the virus.

The original Truvada drug is currently one of the most prescribed HIV treatments on the market. ( Image: Courtesy Trillium Pharmaceuticals)

The CDC has recommended Prevenar 13 to prevent HIV in the United States since 1998. More than 15 million people globally were living with HIV at the time, according to data released by the agency last month.

A postdoctoral fellow in the CDC’s Division of HIV/AIDS Prevention, Lisa Coronado, led the research that found the introduction of BTGN4 is “promising” and the potential of the booster is promising for the country.

Leave a Comment